PathFinderTG® is a molecular analysis of mutations in genomic DNA for cases where traditional pathology results in an "indeterminate," "suspicious," or "atypical" diagnosis. This objective information can help resolve diagnostic dilemmas and lead to a more personalized treatment plan.
PathFinderTG integrates the power of DNA analysis with the expert judgment of traditional pathology to deliver improved diagnostic information. This patented test utilizes a broad panel of microsatellite markers to perform mutational analysis on many types of pathology specimens. Unlike tests for inherited genetic predisposition to cancer, it is an analysis of acquired genomic damage in an individual patient’s tumor.
PathFinderTG can help distinguish:
- Benign versus malignant lesions
- Metastatic, synchronous and recurrent tumors
- Reactive versus neoplastic lesions
- Grade of dysplasia of a lesion
PathFinderTG can differentiate metastatic, synchronous, and recurrent tumors in various organs such as:
PathFinderTG is validated for many organs, including:
- Biliary ducts
PathFinderTG works with a wide variety of standard pathology specimens - even minute solid samples and small fluid volumes from specimens such as histology slides, cytology slides, fluid aspirates and brush samples.
PathFinderTG was developed over a 17-year period, and is clinically validated as reported in over 100 peer-reviewed articles. More than 20,000 specimens have been analyzed using PathFinderTG technology.
No other test available imparts the depth of information provided by PathFinderTG. Our microdissection techniques, DNA amplification methods, and broad panel of genomic markers result in a molecular-based diagnosis to supplement traditional pathology methods.
Physicians: To order a PathFinderTG analysis, go to How To Order or contact Client Services at 1-800-495-9885.